Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3406]
News [7759]
Articles [63]
Editorials [9]
Conferences [207]
elearning [49]
Importance of personalised medicine and the WIN Consortium
Dr John Mendelsohn, Dr Richard Schilsky and Dr Richard Buller
Importance of personalised medicine and the WIN Consortium ( Dr John Mendelsohn, Dr Richard Schilsky and Dr Richard Buller )
30 Apr 2013
Achievements of the WIN Consortium
Dr John Mendelsohn, Dr Richard Schilsky and Dr Richard Buller
Achievements of the WIN Consortium ( Dr John Mendelsohn, Dr Richard Schilsky and Dr Richard Buller )
30 Apr 2013
Goal of the 2013 WIN Symposium
Dr John Mendelsohn, Dr Richard Schilsky, Dr Richard Buller
Goal of the 2013 WIN Symposium ( Dr John Mendelsohn, Dr Richard Schilsky, Dr Richard Buller )
23 Apr 2013
Approaches to treatment of brain metastasis
Dr Elisabetta Munzone - European Institute of Oncology, Milan, Italy
Approaches to treatment of brain metastasis ( Dr Elisabetta Munzone - European Institute of Oncology, Milan, Italy )
23 Apr 2013
Myc inhibition in pre-clinical mouse models
Dr Laura Soucek - Vall d'Hebron Institute of Oncology
Myc inhibition in pre-clinical mouse models ( Dr Laura Soucek - Vall d'Hebron Institute of Oncology )
22 Apr 2013
Immunotherapy in melanoma and other cancers
Dr Suzanne Topalian – Johns Hopkins, Baltimore, USA
Immunotherapy in melanoma and other cancers ( Dr Suzanne Topalian – Johns Hopkins, Baltimore, USA )
19 Apr 2013
Next generation PI3 kinase inhibition
Dr Maurizio Scaltriti – Massachusetts General Hospital, Boston, MA, US
Next generation PI3 kinase inhibition ( Dr Maurizio Scaltriti – Massachusetts General Hospital, Boston, MA, US )
19 Apr 2013
Targeting tumour suppressor genes
Dr Douglas Lowy - National Cancer Institute, Bethesda, USA
Targeting tumour suppressor genes ( Dr Douglas Lowy - National Cancer Institute, Bethesda, USA )
19 Apr 2013
Intermittent treatment with vemurafenib may prevent lethal drug resistance in...
Dr Darrin Stuart - Novartis Institutes for Biomedical Research, Emeryville, CA...
Intermittent treatment with vemurafenib may prevent lethal drug resistance in melanoma ( Dr Darrin Stuart - Novartis Institutes for Biomedical Research, Emeryville, CA, USA )
8 Apr 2013
Potential novel inhibitor to overcome drug resistance induced by RAF, MEK...
Dr Ahmed Samatar - Merck Research Laboratories, Boston, USA
Potential novel inhibitor to overcome drug resistance induced by RAF, MEK Inhibitors ( Dr Ahmed Samatar - Merck Research Laboratories, Boston, USA )
8 Apr 2013
Sapacitabine and seliciclib, antitumour activity in patients with incurable...
Dr Geoffrey Shapiro - Dana-Farber Cancer Institute, Boston, USA
Sapacitabine and seliciclib, antitumour activity in patients with incurable BRCA-deficient cancers ( Dr Geoffrey Shapiro - Dana-Farber Cancer Institute, Boston, USA )
8 Apr 2013
AKT inhibitor AZD5363 in patients with advanced solid tumours
Dr Udai Banerji - Institute of Cancer Research, Sutton, United Kingdom
AKT inhibitor AZD5363 in patients with advanced solid tumours ( Dr Udai Banerji - Institute of Cancer Research, Sutton, United Kingdom )
8 Apr 2013

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation